Alkermes plc (NASDAQ:ALKS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $36.70.
A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Alkermes from $31.00 to $32.00 and gave the company a "neutral" rating in a research report on Thursday, July 25th. Robert W. Baird upped their price objective on shares of Alkermes from $37.00 to $38.00 and gave the company an "outperform" rating in a research note on Thursday, July 25th. HC Wainwright reissued a "neutral" rating and issued a $37.00 target price on shares of Alkermes in a research note on Monday, October 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $48.00 price objective on shares of Alkermes in a report on Thursday, October 10th. Finally, StockNews.com raised shares of Alkermes from a "hold" rating to a "buy" rating in a research note on Sunday, July 28th.
Check Out Our Latest Research Report on ALKS
Alkermes Price Performance
NASDAQ:ALKS traded up $0.39 on Tuesday, hitting $28.10. The company had a trading volume of 1,202,444 shares, compared to its average volume of 1,816,839. The firm has a 50 day moving average of $27.79 and a two-hundred day moving average of $25.84. Alkermes has a 52 week low of $22.01 and a 52 week high of $32.88. The company has a current ratio of 2.99, a quick ratio of 2.61 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $4.76 billion, a price-to-earnings ratio of 10.95, a PEG ratio of 0.56 and a beta of 0.46.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The company had revenue of $399.13 million during the quarter, compared to the consensus estimate of $393.30 million. During the same period last year, the business posted $0.38 EPS. The firm's revenue for the quarter was down 35.4% compared to the same quarter last year. On average, research analysts anticipate that Alkermes will post 2.36 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALKS. EFG Asset Management North America Corp. raised its stake in Alkermes by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 75,864 shares of the company's stock valued at $1,828,000 after purchasing an additional 359 shares during the last quarter. United Services Automobile Association increased its holdings in Alkermes by 3.1% in the 2nd quarter. United Services Automobile Association now owns 13,208 shares of the company's stock valued at $318,000 after purchasing an additional 400 shares during the last quarter. Signaturefd LLC lifted its stake in Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company's stock worth $34,000 after acquiring an additional 480 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Alkermes by 0.3% during the third quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company's stock worth $6,175,000 after purchasing an additional 700 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company's stock worth $55,000 after buying an additional 703 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.
About Alkermes
(
Get Free ReportAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
